AdvanSix Q3 2026 Earnings: Sales Rise 15% as Margins Contract

AdvanSix (NYSE: ASIX) reported Q3 2026 sales of $430.8 million, up 15% from $374.5 million a year earlier, while diluted EPS deteriorated to a loss of $0.28 from a loss of $0.10. Pricing drove the revenue increase, but reduced production output and higher raw-material costs weakened profitability; disciplined working capital and lower capital expenditures supported a substantial improvement in quarterly free cash flow.

Core Financial Results

Revenue, profitability, and cash generation moved in different directions during the quarter. Favorable pricing of 17% more than offset a 2% volume decline, but adjusted EBITDA fell by $10.1 million and its margin contracted by 320 basis points. Meanwhile, operating cash flow increased by $21.4 million.

The following figures cover the three months ended September 30 and use GAAP measures unless otherwise noted.

Adjusted EBITDA, adjusted EPS, and free cash flow are non-GAAP measures. AdvanSix defines free cash flow as operating cash flow less capital expenditures.

Business and Product-Line Performance

Nylon and Chemical Intermediates produced the largest reported sales increases. Plant Nutrients also grew, while Caprolactam revenue was essentially unchanged. Management said lower caprolactam sales were the main reason total company volume declined.

Plant Nutrients remained the largest product line at 35% of quarterly revenue. Nylon increased its contribution to 24% from 21% a year earlier, while Caprolactam’s share declined to 17% from 20%.

Pricing Drove Growth but Could Not Protect Margins

The 17% favorable pricing contribution consisted of a 10% increase from raw-material pass-through pricing and a 7% increase from market-based pricing. The pass-through increase followed higher net costs for benzene and propylene, which are inputs to cumene, while market-based pricing improved across all product lines.

Despite this pricing response, adjusted EBITDA declined approximately 41%. AdvanSix attributed the contraction primarily to reduced production output, which caused unfavorable fixed-cost absorption, and higher raw-material costs. Higher pricing and savings from the company’s non-manpower fixed-cost program provided only a partial offset.

This explains the quarter’s central divergence: sales increased because the company passed through inflation and secured higher market pricing, but lower production and input-cost pressure reduced the earnings generated from those sales.

Cash Flow and Balance Sheet

Operating cash flow rose to $48.0 million despite the quarterly net loss, primarily because of disciplined working-capital performance. The cash flow statement included a $44.3 million source from accounts payable and a $12.7 million source from inventories, partially offset by uses of cash from receivables and accrued liabilities.

Capital expenditures declined to $18.3 million from $26.5 million, reflecting risk-based prioritization of base investments and continued spending on growth programs including SUSTAIN. The combination of stronger operating cash flow and lower capital spending lifted quarterly free cash flow to $29.7 million.

The quarterly improvement should be viewed alongside the year-to-date figures. For the first nine months of 2026, operating cash flow was $42.7 million versus $59.1 million a year earlier, while free cash flow remained negative at $32.3 million compared with negative $29.7 million.

At September 30, cash and cash equivalents were $22.6 million, compared with $19.8 million at December 31, 2025. Inventories declined to $181.4 million from $236.5 million over the same period.

AdvanSix also refinanced its credit facility on August 14 through a new five-year, $425 million secured facility consisting of a $275 million revolving credit facility and a $150 million term loan. Separately, Project CENTURY was selected for a $47 million FIELDS grant to support investment in the company’s ammonia platform; the release did not specify the timing of grant proceeds.

Outlook

AdvanSix now expects approximately $90 million of capital expenditures in 2026, compared with $116 million spent in 2025. It also reaffirmed an expected pretax impact of approximately $17 million from plant turnarounds, below the $25 million impact recorded in 2025.

For its end markets, the company expects tighter ammonium sulfate supply-and-demand conditions into 2027, although sulfur input costs remain challenging. It expects acetone spreads over propylene costs to remain near cycle averages and plans to continue optimizing Nylon Solutions pricing, raw-material spreads, and sales mix amid soft industrial demand.

Management said the non-manpower fixed-cost savings program remains on track and expects future Section 45Q carbon-capture tax credits to support earnings and cash flow. No amount or timing was provided for those credits.

Risks Investors Need to Watch

• Raw-material inflation: Higher benzene and propylene costs already required additional pass-through pricing, while management described the sulfur-cost environment as challenging. Delays or limitations in passing through costs could continue to pressure margins.
• Production and fixed-cost absorption: Reduced production output was a primary reason adjusted EBITDA declined. Continued production weakness would leave fixed manufacturing costs spread over fewer units.
• Soft industrial demand and lower volume: Total volume declined 2%, mainly because of Caprolactam, and management continues to describe the Nylon Solutions industrial environment as soft.
• Cash-flow sustainability: Q3 free cash flow improved sharply, but nine-month free cash flow remained negative. Future improvement depends partly on working-capital tailwinds and a reduced capital-expenditure run rate.
• Execution on investment programs: AdvanSix is advancing SUSTAIN, evaluating a potential DEF project, and progressing Project CENTURY while managing its balance sheet and cost position. The timing and capital requirements of these initiatives remain important variables.

Summary

AdvanSix generated 15% sales growth in Q3 2026 through raw-material pass-through and market-based pricing, but lower production output and elevated input costs drove a wider net loss and substantial adjusted EBITDA margin contraction. Working-capital discipline and reduced capital spending produced much stronger quarterly cash flow, although year-to-date free cash flow remained negative. The main issues to monitor are production levels, raw-material spreads, soft industrial demand, and whether lower capital spending and cost savings can sustain the expected cash-flow improvement.